95 results match your criteria: "Fédération Hospitalo-Universitaire "Innovative therapy for immune disorders"[Affiliation]"
Kidney Int Rep
November 2024
Universite Paris Est Creteil, INSERM IMRB U955, Créteil, France.
Blood
January 2025
Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalier Universitaire Henri Mondor, Université Paris Est-Créteil, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris, Créteil, France.
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
View Article and Find Full Text PDFJ Am Soc Nephrol
October 2024
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
Front Bioeng Biotechnol
September 2024
Institut Pasteur, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR) 1222, Antibodies in Therapy and Pathology, Paris, France.
Droplet-based microfluidics techniques coupled to microscopy allow for the characterization of cells at the single-cell scale. However, such techniques generate substantial amounts of data and microscopy images that must be analyzed. Droplets on these images usually need to be classified depending on the number of cells they contain.
View Article and Find Full Text PDFInflamm Bowel Dis
September 2024
Medizinische Universität Wien Klinische Abt. Gastroenterologie & Hepatologie, AKH Wien Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen (CED) Währinger Gürtel 18-20, Wien, Austria.
Ann Hematol
October 2024
Univ Paris Est Créteil, Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, F-94010, France.
Am J Transplant
January 2025
Nephrology and Kidney Transplantation Laboratory, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain; Department of Nephrology and Kidney Transplantation, University Hospital Vall d'Hebron, Barcelona, Spain. Electronic address:
High human leukocyte antigen (HLA) sensitization limits access to compatible transplantation. New CD38-targeting agents have been shown to reduce anti-HLA antibodies, although with important interpatient variability. Thus, pretreatment identification of responder and nonresponder (NR) patients is needed for treatment decision-making.
View Article and Find Full Text PDFJ Exp Med
September 2024
Centre International de Recherche en Infectiologie, Inserm, U1111, CNRS, UMR5308, École Normale Supérieure de Lyon , Lyon, France.
An exome sequencing strategy employed to identify pathogenic variants in patients with pediatric-onset systemic lupus or Evans syndrome resulted in the discovery of six novel monoallelic mutations in PTPN2. PTPN2 is a phosphatase that acts as an essential negative regulator of the JAK/STAT pathways. All mutations led to a loss of PTPN2 regulatory function as evidenced by in vitro assays and by hyperproliferation of patients' T cells.
View Article and Find Full Text PDFNephrol Dial Transplant
July 2024
Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.
Background And Hypothesis: The estimation of glomerular filtration rate (GFR) is one main tool to detect renal disease. The most used biomarker remains serum creatinine and the European Kidney Function Consortium (EKFCcrea) equation is the most validated in Europe. More recently, cystatin C, has been proposed.
View Article and Find Full Text PDFEur J Clin Invest
October 2024
Department of Nephrology-Dialysis-Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium.
Background: The glomerular filtration rate (GFR) is estimated by the serum or plasma concentration of creatinine and/or cystatin C using equations that include demographic data. The equations worldwide most widely used are those of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) consortium and updated in 2021 to remove the Afro-American racial correction factor. In 2021 and then in 2023, the European Kidney Function Consortium also developed equations based on creatinine and cystatin C, usable across the full age spectrum, and constructed by including the Q value (i.
View Article and Find Full Text PDFAnn Rheum Dis
September 2024
Médecine Interne, CEREMAIA, Sorbonne Université, Hospital Tenon, Paris, France
Objectives: Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies.
Methods: Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy.
Transpl Int
May 2024
Assistance Publique Hôpitaux de Paris, Service de Néphrologie et de Transplantation Rénale, Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », Centre Hospitalo-Universitaire Henri Mondor, Créteil, France.
Due to its intrinsic complexity and the principle of collective solidarity that governs it, solid organ transplantation (SOT) seems to have been spared from the increase in litigation related to medical activity. Litigation relating to solid organ transplantation that took place in the 29 units of the Assistance Publique-Hôpitaux de Paris and was the subject of a judicial decision between 2015 and 2022 was studied. A total of 52 cases of SOT were recorded, all in adults, representing 1.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
December 2024
Department of Gastroenterology, INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD).
Methods: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks.
J Am Soc Nephrol
August 2024
Inflammation, Complement and Cancer Team, Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université Paris Cité, Paris, France.
Key Points: We evidenced terminal pathway activation (C5b-9 deposits) in most of the glomeruli on kidney biopsy of C3 glomerulopathy. The amount of C5b-9 deposits correlated with disease prognosis in C3 glomerulopathy. Increased terminal pathway activation was found predominantly in a subgroup exhibiting an immuno-fibroblastic signature.
View Article and Find Full Text PDFSci Immunol
April 2024
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT).
View Article and Find Full Text PDFTranspl Int
March 2024
AP-HP, Service de Néphrologie et de Transplantation Rénale, Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », CHU Henri Mondor, Créteil, France.
Late opportunistic infections (OI) occurring beyond the first year after kidney transplantation (KT) are poorly described and not targeted by prophylactic strategies. We performed a ten-year retrospective monocentric cohort study describing epidemiology, risk factors and impact of late OI occurring 1 year after KT. We included clinically symptomatic OI requiring treatment besides BK virus nephropathy.
View Article and Find Full Text PDFRMD Open
March 2024
EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France.
Nephrol Ther
February 2024
Service de néphrologie-dialyse-transplantation, CHU Rouen, France ; Normandie Univ, UNIROUEN, Inserm U1096, Rouen, France
Kidney Biopsy (KB) is a crucial diagnostic tool in the field of renal diseases and is routinely performed in nephrology departments. A previous survey conducted by the Société Francophone de Néphrologie Dialyse Transplantation (SFNDT) revealed significant disparities in clinical practices, sometimes conflicting with the existing literature and recently published recommendations. In response, the SFNDT wished to promote the development of best practice guidelines, under the auspices of the French National Authority for Health (HAS), to establish a standardized framework for performing kidney biopsies in France.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
May 2024
French National Reference Center for Hypereosinophilic Syndromes, Department of Internal Medicine, Foch Hospital, Suresnes, France. Electronic address:
Nephron
June 2024
Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.
Background: In daily practice, glomerular filtration rate (GFR) is estimated with equations including renal biomarkers. Among these biomarkers, serum creatinine remains the most used. However, there are many limitations with serum creatinine, which we will discuss in the current review.
View Article and Find Full Text PDFAm J Kidney Dis
June 2024
Department of Pathology, Centre Hospitalier Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM U1151, CNRS UMR 8253, Institut Necker-Enfants Malades, Département Croissance et Signalisation, University of Paris Cité, Paris, France.
Br J Haematol
February 2024
Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France.
Deficiency in regulatory B cells has been suggested in immune thrombocytopenia. In this study, Stimpson et al. emphasize the importance of considering the treatments received for immunological analyses.
View Article and Find Full Text PDFCell Rep Med
December 2023
Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, 75015 Paris, France; Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, 75015 Paris, France. Electronic address:
Gain-of-function mutations in stimulator of interferon gene 1 (STING1) result in STING-associated vasculopathy with onset in infancy (SAVI), a severe autoinflammatory disease. Although elevated type I interferon (IFN) production is thought to be the leading cause of the symptoms observed in patients, STING can induce a set of pathways, which have roles in the onset and severity of SAVI and remain to be elucidated. To this end, we performed a multi-omics comparative analysis of peripheral blood mononuclear cells (PBMCs) and plasma from SAVI patients and healthy controls, combined with a dataset of healthy PBMCs treated with IFN-β.
View Article and Find Full Text PDFRadiology
December 2023
From the Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Université Paris Est Créteil, Institut Mondor de Recherche Biomédicale, Créteil, France (T.S., F.W., A.L., P.G., E.R., S.M., A.H., A.B., M.B., C.M.C., A.I., M.M., P.B., F.C.P., F.P.); Service de Néphrologie et Transplantation (T.S., P.G., A.D., A.B., M.M.), Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders (T.S., P.G., A.D., A.B., M.M.), Service d'Imagerie Médicale (F.W., A.L., E.R., S.M., M.B., F.P.), Laboratoire de Pharmacologie (A.H.), Service d'Urologie (C.M.C., A.I.), Service de Santé Publique (P.B., F.C.P.), and Unité de Recherche Clinique (P.B., F.C.P.), Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri-Mondor, Créteil, France; Service de Physiologie et Explorations Fonctionnelles, AP-HP, Groupe Hospitalier Necker Enfants Malades, Paris, France (S.B., D.P.); Faculté de Médecine, Université de Paris Cité, INSERM U1151, Paris, France (D.P.); Faculté de Médecine, Université Paris-Saclay, Orsay, France (A.D.); and INSERM UMR 1186, Institut Gustave Roussy, Villejuif, France (A.D.).
Background Estimating glomerular filtration rate (GFR) from serum creatinine can be inaccurate, and current procedures for measuring GFR are time-consuming and cumbersome. Purpose To develop a method for measuring GFR based on iomeprol clearance assessed at CT urography in kidney donor candidates and compare this with iohexol clearance (reference standard for measuring GFR). Materials and Methods This cross-sectional retrospective study included data from kidney donor candidates who underwent both iohexol clearance and CT urography between July 2016 and October 2022.
View Article and Find Full Text PDFNephrol Dial Transplant
June 2024
Service de Néphrologie, Dialyse et Transplantation Rénale, Hôpital Nord, CHU de Saint-Etienne, France.